Compare OWL & LNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OWL | LNTH |
|---|---|---|
| Founded | 2020 | 1956 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.9B | 5.6B |
| IPO Year | 2020 | 2014 |
| Metric | OWL | LNTH |
|---|---|---|
| Price | $10.05 | $94.94 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 15 | 6 |
| Target Price | $14.79 | ★ $87.00 |
| AVG Volume (30 Days) | ★ 28.4M | 897.2K |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | ★ 10.13% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 0.02 | ★ 1.80 |
| Revenue | ★ $567,754,000.00 | $343,374,000.00 |
| Revenue This Year | $5.43 | N/A |
| Revenue Next Year | $13.85 | $14.19 |
| P/E Ratio | $509.00 | ★ $52.32 |
| Revenue Growth | ★ 7.56 | 3.62 |
| 52 Week Low | $7.95 | $47.27 |
| 52 Week High | $21.08 | $98.27 |
| Indicator | OWL | LNTH |
|---|---|---|
| Relative Strength Index (RSI) | 54.20 | 63.88 |
| Support Level | $8.65 | $72.35 |
| Resistance Level | $10.33 | $98.27 |
| Average True Range (ATR) | 0.45 | 3.14 |
| MACD | -0.02 | -0.07 |
| Stochastic Oscillator | 46.48 | 71.17 |
Blue Owl Capital is one of the world's largest alternative-asset managers, $307.4 billion in total managed assets, including $187.7 billion in fee-earning AUM, at the end of 2025. The company has three core business segments: global private equity, (with $69.1 billion in total AUM and $39.5 billion in fee-earning AUM), private credit ($157.7 billion/$99.5 billion), and real estate/real assets ($80.6 billion/$48.7 billion). The firm primarily serves institutional investors (68% of AUM) and high-net-worth individuals (32%). Blue Owl operates through more than 20 offices in the Americas, and the EMEA and Asia-Pacific regions.
Lantheus Holdings Inc is a radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver patient outcomes. The Company classifies its products into Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Its products help healthcare professionals Find, Fight and Follow cancer and diseases and are used by physicians and technologists in clinical settings. The Company produces and markets its products in the United States, mainly to hospitals, independent imaging centers and government facilities, and sells outside the United States through direct and third-party distribution relationships and licensing arrangements in Europe, Canada, Australia, Asia-Pacific, Central America and South America.